Hot Features
プレミアム
登録してリアルタイムのチャート、分析ツール、価格を入手してください。
期間:
書込みモード:
| 出来高 | 26,074 |
|
|||||
| ニュース | - |
| 名称 | 銘柄コード | 市場 | 種別 |
|---|---|---|---|
| Reviva Pharmaceuticals Holdings Inc | RVPHW | NASDAQ | Equity Warrant |
| 前日比 | 前日比 % | 現在値 | 時刻
|
|
|---|---|---|---|---|
| -0.0249 | -9.22% | 0.2451 | 06:47:28 |
| 始値 | 安値 | 高値 | 終値 | 前日終値 |
|---|---|---|---|---|
| 0.265 | 0.2298 | 0.265 | 0.2451 | 0.27 |
| 取引数 | 出来高 | VWAP | Financial Volume | 平均音量 |
|---|---|---|---|---|
| 49 | 26,074 | 0.232167 | 6,054 | - |
| 最終取引 | タイプ | 数量 | 価格 | 通貨 |
|---|---|---|---|---|
| 06:00:00 | 100 | 0.2451 | USD |
企業情報 - Reviva Pharmaceuticals Holdings Inc
| 時価総額 | 発行済株式数 | Float | 歳入 | 利益/損失 | 一株当たり利益 | PER |
|---|---|---|---|---|---|---|
| 6.12M | 22.65M | - | 0 | -39.26M | -1.73 | - |
| Short Interest | 1株あたり配当 | 配当利回り | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
ニュース - Reviva Pharmaceuticals
| 日付 | 時間 | 情報元 | タイトル |
|---|---|---|---|
| 2024/12/21 | 06:30 | Edgar (US Regulatory) | Form SCHEDULE 13D/A - General Statement of Acquisition of.. |
| 2024/12/18 | 20:00 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2024/12/17 | 07:18 | Edgar (US Regulatory) | Form 424B5 - Prospectus [Rule 424(b)(5)] |
| 2024/12/16 | 22:10 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2024/12/13 | 06:36 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2024/12/13 | 06:35 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2024/12/13 | 06:35 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2024/12/13 | 06:34 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of.. |
| 2024/11/15 | 07:25 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2024/11/15 | 07:15 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] |
| 2024/11/12 | 22:30 | Edgar (US Regulatory) | Form 8-K - Current report |
| 2024/10/29 | 05:17 | Edgar (US Regulatory) | Form DEF 14A - Other definitive proxy statements |
チャート - Reviva Pharmaceuticals
| 期間 † | 始値 | 高値 | 安値 | VWAP | 平均出来高 | 前日比 | % |
|---|---|---|---|---|---|---|---|
| 1週 | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1ヶ月 | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3ヶ月 | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 6ヶ月 | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 1年 | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 3年 | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
| 5年 | 0.00 | 0.00 | 0.00 | 0.00 | 0 | 0.00 | 0.00% |
NASDAQ:RVPHW -
What is the current Reviva Pharmaceuticals Holdings Inc share price?
The current share price of Reviva Pharmaceuticals Holdings Inc is US$ 0.2451
How many Reviva Pharmaceuticals Holdings Inc shares are in issue?
Reviva Pharmaceuticals Holdings Inc has 22,650,000 shares in issue
What is the market cap of Reviva Pharmaceuticals Holdings Inc?
The market capitalisation of Reviva Pharmaceuticals Holdings Inc is USD 6.12M
What is the 1 year trading range for Reviva Pharmaceuticals Holdings Inc share price?
Reviva Pharmaceuticals Holdings Inc has traded in the range of US$ 0.00 to US$ 0.00 during the past year
What is the PE ratio of Reviva Pharmaceuticals Holdings Inc?
The price to earnings ratio of Reviva Pharmaceuticals Holdings Inc is -5.05
What is the reporting currency for Reviva Pharmaceuticals Holdings Inc?
Reviva Pharmaceuticals Holdings Inc reports financial results in USD
What is the latest annual profit for Reviva Pharmaceuticals Holdings Inc?
The latest annual profit of Reviva Pharmaceuticals Holdings Inc is USD -39.26M
What is the registered address of Reviva Pharmaceuticals Holdings Inc?
The registered address for Reviva Pharmaceuticals Holdings Inc is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808
What is the Reviva Pharmaceuticals Holdings Inc website address?
The website address for Reviva Pharmaceuticals Holdings Inc is revivapharma.com
Which industry sector does Reviva Pharmaceuticals Holdings Inc operate in?
Reviva Pharmaceuticals Holdings Inc operates in the PHARMACEUTICAL PREPARATIONS sector
